Prevention

DEBATE: Should VTE treatment continue beyond 6 months? Evidence supporting anticoagulation discontinuation

During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...

In recent years, the incidence of venous thromboembolism (VTE) has been rising in patients with cancer. A Danish cohort...

The tight association between malignancies and hypercoagulation was highlighted almost a century ago by the...

Cancer-associated thrombosis (CAT) is an important and increasingly common complication of cancer and cancer...

Although patients with cancer have a four-to-five-fold increased risk of venous thromboembolism (VTE) compared with the...

Estimation of prognosis is of utmost importance when managing patients with advanced cancer: it helps make decisions...

During the ICTHIC webinar “Joint forces: the Patient & the Multi-disciplinary Team working together to...

Myeloproliferative neoplasms (MPNs) are characterized by clonal expansion of abnormal hematopoietic stem cells, which...

The HYPERCAN (HYPERcoagulation in CANcer) study (registered at www.clinicaltrials.gov; NCT02622815) is an ongoing,...

The American Society of Clinical Oncology just published the new recommendations regarding VTE prophylaxis and...